BACKGROUND: Yes-associated protein (YAP), a downstream target of the Hippo signaling pathway, was recently linked to hepatocarcinogenesis in a mouse hepatocellular carcinoma (HCC) model. The objective of the current study was to investigate the clinical significance of YAP in HCC and its prognostic values in predicting survival and tumor recurrence. METHODS: The authors collected 177 pairs of tumor and adjacent nontumor tissue from HCC patients with definitive clinicopathologic and follow-up data. YAP expression was determined by immunohistochemistry, Western blot analysis, and quantitative polymerase chain reaction. Association of YAP with each clinicopathologic feature was analyzed by Pearson chi-square test, and HCC-specific disease-free survival and overall survival by Kaplan-Meier curves and log-rank test. Multivariate Cox regression analyses of YAP in HCC were also performed. RESULTS: YAP was expressed in the majority of HCC cases (approximately 62%) and mainly accumulated in the tumor nucleus. Overexpression of YAP in HCC was significantly associated with poorer tumor differentiation (Edmonson grade; P = .021) and high serum alpha-fetoprotein (AFP) level (P < .001). Kaplan-Meier and Cox regression data indicated that YAP was an independent predictor for HCC-specific disease-free survival (hazards ratio [HR], 1.653; 95% confidence interval [95% CI], 1.081-2.528 [P = .02]) and overall survival (HR, 2.148; 95% CI, 1.255-3.677 [P = .005]). CONCLUSIONS: YAP is an independent prognostic marker for overall survival and disease-free survival times of HCC patients and clinicopathologically associated with tumor differentiation and serum AFP level. It is a potential therapeutic target for this aggressive malignancy. 2009 American Cancer Society.
BACKGROUND:Yes-associated protein (YAP), a downstream target of the Hippo signaling pathway, was recently linked to hepatocarcinogenesis in a mousehepatocellular carcinoma (HCC) model. The objective of the current study was to investigate the clinical significance of YAP in HCC and its prognostic values in predicting survival and tumor recurrence. METHODS: The authors collected 177 pairs of tumor and adjacent nontumor tissue from HCC patients with definitive clinicopathologic and follow-up data. YAP expression was determined by immunohistochemistry, Western blot analysis, and quantitative polymerase chain reaction. Association of YAP with each clinicopathologic feature was analyzed by Pearson chi-square test, and HCC-specific disease-free survival and overall survival by Kaplan-Meier curves and log-rank test. Multivariate Cox regression analyses of YAP in HCC were also performed. RESULTS:YAP was expressed in the majority of HCC cases (approximately 62%) and mainly accumulated in the tumor nucleus. Overexpression of YAP in HCC was significantly associated with poorer tumor differentiation (Edmonson grade; P = .021) and high serum alpha-fetoprotein (AFP) level (P < .001). Kaplan-Meier and Cox regression data indicated that YAP was an independent predictor for HCC-specific disease-free survival (hazards ratio [HR], 1.653; 95% confidence interval [95% CI], 1.081-2.528 [P = .02]) and overall survival (HR, 2.148; 95% CI, 1.255-3.677 [P = .005]). CONCLUSIONS:YAP is an independent prognostic marker for overall survival and disease-free survival times of HCC patients and clinicopathologically associated with tumor differentiation and serum AFP level. It is a potential therapeutic target for this aggressive malignancy. 2009 American Cancer Society.
Authors: Fernando D Camargo; Sumita Gokhale; Jonathan B Johnnidis; Dongdong Fu; George W Bell; Rudolf Jaenisch; Thijn R Brummelkamp Journal: Curr Biol Date: 2007-11-01 Impact factor: 10.834
Authors: Xin Yi; John M Luk; Nikki P Lee; Jirun Peng; Xisheng Leng; Xin-Yuan Guan; George K Lau; Laura Beretta; Sheung-Tat Fan Journal: Mol Cell Proteomics Date: 2007-10-14 Impact factor: 5.911
Authors: David Fu; Xiangmin Lv; Guohua Hua; Chunbo He; Jixin Dong; Subodh M Lele; David Wan-Cheng Li; Qiongli Zhai; John S Davis; Cheng Wang Journal: Endocr Relat Cancer Date: 2014-03-04 Impact factor: 5.678
Authors: Yun-Yong Park; Bo Hwa Sohn; Randy L Johnson; Myoung-Hee Kang; Sang Bae Kim; Jae-Jun Shim; Lingegowda S Mangala; Ji Hoon Kim; Jeong Eun Yoo; Cristian Rodriguez-Aguayo; Sunila Pradeep; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Woojin Jeong; Inn Sun Park; Young Nyun Park; Anil K Sood; Gordon B Mills; Ju-Seog Lee Journal: Hepatology Date: 2015-11-26 Impact factor: 17.425
Authors: Felice H Tsang; Victor Au; Wen-Jing Lu; Felix H Shek; Angela M Liu; John M Luk; Sheung-Tat Fan; Ronnie T P Poon; Nikki P Lee Journal: Dig Dis Sci Date: 2014-05-09 Impact factor: 3.199
Authors: James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik Journal: J Biol Chem Date: 2017-04-21 Impact factor: 5.157
Authors: Li Lu; Ying Li; Soo Mi Kim; Wouter Bossuyt; Pu Liu; Qiong Qiu; Yingdi Wang; Georg Halder; Milton J Finegold; Ju-Seog Lee; Randy L Johnson Journal: Proc Natl Acad Sci U S A Date: 2010-01-04 Impact factor: 11.205